HRT Financial’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-108,012
Closed -$2.62M 2759
2025
Q1
$2.62M Buy
+108,012
New +$2.43M 0.02% 692
2024
Q4
Sell
-105,743
Closed -$2.1M 2537
2024
Q3
$2.1M Buy
+105,743
New +$1.96M 0.01% 867
2024
Q1
Sell
-37,623
Closed -$632K 2431
2023
Q4
$632K Sell
37,623
-20,003
-35% -$273K ﹤0.01% 1242
2023
Q3
$673K Buy
57,626
+41,747
+263% +$558K 0.01% 1232
2023
Q2
$213K Sell
15,879
-206,299
-93% -$2.97M ﹤0.01% 1812
2023
Q1
$3.68M Buy
222,178
+188,073
+551% +$3.1M 0.04% 344
2022
Q4
$634K Buy
34,105
+888
+3% +$13.7K 0.01% 1260
2022
Q3
$426K Sell
33,217
-154,902
-82% -$1.84M ﹤0.01% 1755
2022
Q2
$1.32M Buy
+188,119
New +$1.38M 0.01% 763
2022
Q1
Sell
-132,366
Closed -$896K 3220
2021
Q4
$896K Buy
132,366
+98,986
+297% +$651K 0.01% 1231
2021
Q3
$176K Buy
+33,380
New +$183K ﹤0.01% 2737
2021
Q1
Sell
-108,714
Closed -$363K 2748
2020
Q4
$363K Buy
+108,714
New +$365K 0.01% 1189
2020
Q3
Sell
-49,888
Closed -$230K 1957
2020
Q2
$230K Buy
+49,888
New +$224K 0.01% 1095

Other funds holding CPRX

HRT Financial's CPRX Position: Q2 2025 in Review

HRT Financial sold out of Catalyst Pharmaceutical (CPRX) in Q2 2025, closing a stake of 108,012 shares — an estimated $2.62M sold.

HRT Financial first reported a position in CPRX in Q2 2020 and held it in 13 quarters. The position peaked at $3.68M in Q1 2023. 365 funds tracked by Wall St. Rank hold CPRX as of Q2 2025.

  • HRT Financial reported no remaining Catalyst Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • HRT Financial sold 108,012 Catalyst Pharmaceutical shares in Q2 2025, an estimated $2.62M.
  • HRT Financial first reported a position in Catalyst Pharmaceutical in Q2 2020 and held it in 13 quarters.
  • HRT Financial's Catalyst Pharmaceutical position peaked at $3.68M in Q1 2023.
  • 365 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2025.

Based on HRT Financial's 13F filing for Q2 2025, filed 14 Aug 2025.